Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | XBP1 | P17861 | 2/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776173 | 0.77 | KDM4E (0.49) | TP53MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL6778686 | 0.76 | DPP4 (0.48) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL1866115 | 0.75 | MAPT (0.50) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL8290591 | 0.75 | PRKCZ (0.71) | MAPTKDM4ESMN1; SMN2POLBHSD17B10 | |
| SCHEMBL5922344 | 0.74 | MAPT (0.50) | TP53MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL12019616 | 0.74 | ALOX15 (0.47) | TP53MAPTKDM4ESMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL11463651 | 0.74 | MAPT (0.53) | TP53MDM2MAPTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11455444 | 0.74 | TP53 (0.51) | TP53MDM2MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL28043446 | 0.72 | NPC1 (0.51) | MAPTSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL16344846 | 0.72 | ALOX15 (0.70) | MAPTLMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734185-B2 | Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-05-11 | — | — | US | disclosed |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6630476-B2 | For therapy of anxiety, depression, and other psychiatric, neurological disorders, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022632-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | TP53 4363/4885MDM2 4306/4885MAPT 3449/4885 |
| US-20030220333-A1 | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists | CRH, CRHR1, CRHR2 | TP53 4457/4885MDM2 4371/4885MAPT 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.